EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia

Francesca Morelli, Silvia Linari, Chiara Maria Rapolla, Monica Attanasio, Francesca Salvianti, Alessandro Sanna

Annals of Hematology · 14.03.2026 · 105 (4)

DOI: 10.1007/s00277-026-06889-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 14.03.2026. Verfasst von Francesca Morelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicLeukemia, Lymphocytic, Chronic, B-CellSulfonamidesvon Willebrand DiseasesAgedHumansRemission InductionTreatment Outcomevon Willebrand Factor

Stichwörter der Autor:innen

Acquired von willebrand syndromeChronic lymphocytic leukemiaVenetoclax-obinutuzumab

Substanzen

Antibodies, Monoclonal, HumanizedBridged Bicyclo Compounds, HeterocyclicobinutuzumabSulfonamidesvenetoclaxvon Willebrand Factor

Autor:innen und Institutionen

  • Department of Hematology, University of Florence, Florence, Italy.
  • Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy.
  • Department of Hematology, Careggi University Hospital, Largo Brambilla 3, Firenze, 50134, Italy. sannaa@aou-careggi.toscana.it.

Zitieren

APA

Morelli, F., Linari, S., Rapolla, C. M., Attanasio, M., Salvianti, F., & Sanna, A. (2026). Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06889-2

Vancouver

Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A. Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06889-2

BibTeX
@article{Morelli2026,
  author = {Morelli, Francesca and Linari, Silvia and Rapolla, Chiara Maria and Attanasio, Monica and Salvianti, Francesca and Sanna, Alessandro},
  title = {Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {4},
  doi = {10.1007/s00277-026-06889-2}
}
Kostenlos starten →